Table 1.
Ongoing clinic trials for TAM-targeted agents
| Target | TAM-Directed Therapy | Cancer | Combination Therapy | Phase | Trial |
|---|---|---|---|---|---|
| TRAIL 1,2 | Trabectedin | Sarcoma | - | 2 | NCT03397186 |
| Mesothelioma | - | 2 | NCT02194231 | ||
| CCR2 | PF-04136309 | Pancreatic | Nab-Paclitaxel/ Gemcitabine | 1 b/2 | NCT02732938 |
| CCR2/5 | BMS 813160 | Pancreatic | Nivolumab/Gemcitabine/Nab-paclitaxel | 1/2 | NCT03496662 |
| CSF-1R | Pexidartinib | Solid Tumors | PLX9486 | 1/2 | NCT02401815 |
| Solid Tumors | - | 1 | NCT01004861 | ||
| Solid/Hematologic | - | 1/2 | NCT02390752 | ||
| Melanoma | - | 1/2 | NCT02975700 | ||
| Glioblastoma | Radiation/Temozolamide | 1/2 | NCT01790503 | ||
| Pancreatic/Colon | Durvalumab | 1 | NCT02777710 | ||
| Breast | Eribulin | 1/2 | NCT01596751 | ||
| Prostate | Antiandrogen/Hormone | 1 | NCT02472275 | ||
| Peripheral Nerve Sheath Tumors |
Sirolimus | 1/2 | NCT02584647 | ||
| Melanoma | Pembrolizumab | 1/2 | NCT02452424 | ||
| Melanoma | - | 2 | NCT02071940 | ||
| Solid Tumors | Atezolizumab | 1 | NCT02323191 | ||
| RG7155 | Female Genital | Paclitaxel/Bevacizumab | 2 | NCT02923739 | |
| Female Genital | Paclitaxel/Bevacizumab | 2 | NCT02923739 | ||
| CD40 | CP-870,893 | Melanoma | Tremelimumab | 1 | NCT01103635 |
| CD47 | CC-90002 | Hematologic | - | 1 | NCT02641002 |
| Solid/Hematologic | Rituximab | 1 | NCT02367196 | ||
| Hu5F9-G4 | Solid/Hematologic | - | 1 | NCT02678338 | |
| TTI-621 | Hematologic | Rituximab/PD-1 Inhibitor/Proteasome Inhibitor |
1 | NCT03530683 | |
| Solid/Hematologic | Rituximab/Nivolumab | 1 | NCT02663518 | ||
| SRF231 | Solid/Hematologic | - | 1 | NCT03512340 | |
| ALX148 | Solid/Hematologic | Rituximab/Trastuzumab/Pembrolizumab | 1 | NCT03013218 | |
| Hu5F9-G4 | Hematologic | Azacitidine | 1 | NCT03248479 | |
| Solid Tumors | Cetuximab | 1/2 | NCT02953782 |